Biocept, Inc.
BIOC · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | -$0 |
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | -12.5% | 106.5% | -284.1% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -332.9% | -349.9% | 141.9% | -3.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -545.2% | -963.4% | 176.6% | -91% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -616.5% | -1,075.2% | 180.1% | -98.7% |
| EPS Diluted | -3,503.04 | -12.32 | -32.57 | -9.73 |
| % Growth | -28,333.8% | 62.2% | -234.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |